State of Art: Clinical ex vivo lung perfusion: Rationale, current status, and future directions

In situ lung perfusion is a valuable tool to assess lungs from donation after circulatory death donors category I-II

“…As the ISLP circuit is closed with regard to nonvolatile metabolites, the rise of lactate must be the result of lactate production from pulmonary glucose degradation and of lactate release during lung injury [19]. Hypoxia is not necessarily the cause of pulmonary lactate production, as also well-oxygenated lungs are known to be net lactate producers [20]. Moreover, hypoxemia owing to pulmonary insufficiency in clinical studies did not correlate with a rise in lactate level or the lactate-pyruvate ratio (L/P ratio) [21,22].…”

Current perspectives in transplant medicine: hypothermic oxygenated perfusion

“…47 EVLP is a clinical routine in some experienced lung transplant centers (e.g., Toronto and Lund), and is a helpful tool to evaluate the quality of marginal donor organs particularly for DCD. 48 In clinical heart transplantation, NMP with the Organ Care …”

Rebuilding a diseased lung: repair and regeneration

“…Fisher (Newcastle University, Newcastle Upon Tyne, UK) highlighted that, although substantial advances in the field of lung transplantation have been made in recent years, the shortage of donor organs, immunosuppressive treatment, as well as long-term graft dysfunction and bronchiolitis obliterans syndrome, still present major hurdles that need to be overcome [17]. Recent progress has been made in ex vivo lung perfusion strategies that may lead to an increased number of donor organs suitable for transplantation and further allow application of novel cell-based therapies in combination with tissue engineering approaches [18]. The focus of the 11th LSC in 2013 will be ''Early origins and mechanisms of chronic lung disease.''…”